Shiva Nathan

Biography
Shiva Nathan is the founder of Onymos, a Silicon Valley-based software company building intelligent automation solutions for healthcare and life sciences. Before founding Onymos, Shiva was Head of Intuit's Platforms Services organization. He has also held technical leadership positions at Oracle and CA. These companies continue to leverage the products he helped define and build. He is an alumnus of BITS Pilani and UC Berkeleys Haas School of Business.

AI and Data Sciences Showcase:
Onymos
Onymos is building innovative automation software for the high-trust, high-stakes environments inside healthcare and life sciences. It helps organizations modernize their workflows and unlock the value of unstructured data without ever compromising security, compliance, or control.

Pi Zonooz

Biography
Pi is a tech veteran, having spent the last 10 years leading technical teams at Accenture, AWS, and Stripe. At AWS, he helped launch over 40 first-party services, including AWS Data Marketplace. Pi led the first epic deployment on AWS and the first Alexa deployment in a healthcare setting.

---

Talk
NimbleLabs: The Agentic OS for Better Healthcare
Healthcare has a problem: clinical data is too fragmented and unstructured for AI reasoning, forcing organizations to spend months cleaning, labeling, and harmonizing data. This is where NimbleLabs comes in: our Nimblemind multi-agent system automates data preparation, transforming multi-modal information into analysis-ready datasets.

AI and Data Sciences Showcase:
Nimblemind
Nimblemind is addressing one of healthcare AI's biggest bottlenecks: preparing usable clinical data. Our approach uses specialty-specific AI agents to transform fragmented multimodal clinical data into structured datasets.

Emily Chen

Biography
Emily Chen is a life sciences professional with over 10 years of experience in NGS service operations. She has led projects across the full workflow—from sample processing to final data delivery—supporting high-throughput NGS applications with a strong focus on quality, efficiency, and collaboration. By optimizing laboratory processes, implementing automation, and streamlining project tracking systems, Emily strives to transform complex and variable biological samples into reliable, actionable data. Her work directly enables genome-, epigenome-, and transcriptome-focused analyses to overcome technical and analytical challenges in molecular diagnostics, improving assay robustness, turnaround time, and data confidence to support accurate decision-making in research and clinical settings.

---

Talk

AI and Data Sciences Showcase:
Zymo Research
Zymo Research, a privately owned biotech company founded in 1994, is a global leader in molecular tools for life sciences. Driven by the principle "The Beauty of Science is to Make Things Simple," Zymo is dedicated to developing innovative solutions that address complex scientific challenges.

Christoph Correll

Biography
Christoph U. Correll, MD, studied medicine at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry. Since 1997, he has been working and conducting research in New York, USA, and since 2017 he is also working in Germany. Dr. Correll focuses on the management of adults and youth with severe mental disorders, psychopharmacology, novel drug development, clinical trials, real-world evidence, and physical health in mental health. He has authored >1,200 articles that have been cited more than 120,000 times and received over 40 research awards. Since 2014, the beginning of this metric, he has been listed every year by Clarivate/Web of Science as one of the “most influential scientific minds” and “top 1% cited scientists in the area of psychiatry”.

---

Talk
AI-Supported Next-Generation Precision Psychiatry
Psychiatric care has long relied on trial and error. This talk explores how clinical evidence, AI, and longitudinal patient understanding could support more personalized decisions. Christoph will share MedLink’s emerging research, what it is building, and lessons from bringing these tools into clinical practice.

AI and Data Sciences Showcase:
Medlink Global

Will Ferguson

Biography
Will Ferguson is a seasoned life sciences executive and Chief Business Officer (CBO) at Specie Bio, bringing over two decades of experience driving commercial growth, corporate strategy, and high-impact partnerships across the genomics and biopharma landscapes. Prior to joining Specie Bio, Will served as Vice President of Pharma/Biotech Collaborations at Illumina, where he led business development and strategic drug discovery partnerships. Throughout his career, he has held key executive and commercial leadership roles at companies including Agilent, Complete Genomics, Genuity Sciences, and BlueBee, demonstrating a proven track record of scaling global sales organizations and executing go-to-market strategies across life science tools, enterprise software, and discovery cohorts. A recognized dealmaker in the multiomics space, Will co-led the formation of the landmark Alliance for Genomic Discovery (AGD)—a 10-biopharma partnership sequencing 313,000 whole genomes—and directed the groundbreaking 1 Billion Cell Atlas initiative alongside AstraZeneca, Eli Lilly, Merck and Formation Bio.

---

Talk
Unlocking the world's untapped biospecimens and biodata
Patients contribute millions of biospecimens and biodata to research, yet many sit unused. BioExchange’s AI matches researchers with global providers holding over 8 million banked samples. Hear how BioExchange helped a top pharmaceutical company complete external comparator arm (ECA) studies by finding rare biomarker-matched patient samples and EMR data.

AI and Data Sciences Showcase:
Specie Bio
Specie Bio connects researchers to biospecimens and biodata across a global provider network with 8 million+ banked samples and 100 million+ annual patient visits, accelerating therapeutic and diagnostic development. BioExchange won the 2026 New Innovation Product Award from ISBER, the international biobanking society.

Badri Padhukasahasram

Biography
Badri Padhukasahasram leads data science strategy and execution at Strand Life Sciences, translating advances in AI and computational biology into pharma-facing solutions for drug discovery, precision medicine, and diagnostics. His portfolio spans single-cell and bulk transcriptomics foundation models, cellular perturbation modeling for drug response prediction, AI-driven early cancer detection, proteomics analytics, and therapeutic target prioritization using genome-wide association studies. With over two decades of experience in computational biology and large-scale omics analysis, Badri specializes in population genomics, complex disease genetics, polygenic risk prediction, genome-wide association studies, pharmacogenomics, non-invasive prenatal testing, and oncology diagnostics. His expertise includes developing statistical methods, algorithms, theoretical frameworks, and simulation tools to extract biological insights from complex omics data. His industry experience includes roles at Illumina and Roche, where he contributed to regulated clinical diagnostics.

---

Talk
Omics-Specific AI Foundation Models advance Precision Medicine
From genome to cell to patient, Strand Life Sciences advances precision medicine through omics-specific AI foundation models. VEINS prioritizes noncoding variants; cellular perturbation models predict drug responses and identify therapeutic targets; CytoRx AI enables single-cell based target discovery; and cfDNA methylation and fragmentomics models support blood-based multi-cancer early detection and minimal residual disease (MRD) monitoring.

AI and Data Sciences Showcase:
Strand Life Sciences
Strand Life Sciences is a Bengaluru-based computational biology and AI company partnering with global pharmaceutical and diagnostics leaders to translate complex multi-omic data into actionable biological and clinical insights. Its specialized AI foundation models and advanced analytics span therapeutic target discovery, biomarker development, drug response prediction, and blood-based early cancer detection, advancing precision medicine from genomic discovery to clinical application.

Archana Dubey

Biography
Archana is a physician-entrepreneur and nationally recognized leader in health technology, AI, and population health strategy. She co-founded a Physical AI company building Darwin, a foundation model harness for continuous, sensor- and context-based health intelligence, and is also the Founding Partner of Arches Accelerator, a commercialization engine for early-stage health-tech innovation. Over a 30-year career, Archana has served as Chief Medical Officer and a member of the Board of Directors at UnitedHealthcare, Chief Clinical Officer at AliveCor, and Global Medical Director at HP Inc., advising Fortune 100 leadership at companies including Google, Tesla, and Netflix. She conceived and launched Kardia Complete at AliveCor and drove consecutive years of profitability across a 2.1 million-member health plan at UnitedHealthcare. A Board-Certified Family Physician, former Adjunct Clinical Assistant Professor at Stanford, and Fellow of the American Academy of Family Physicians, Archana brings rare depth across clinical medicine, reimbursement, regulatory affairs, and AI commercialization.

---

Talk
Physical AI Platform for Personalized Health Intelligence
Precision medicine reads genomes and lab tests, but rarely the body's continuous signals. We show how a physical AI platform built on foundation models turns data from any combination of sensors, such as ECG, EEG, EMG, PPG and motion, into personalized endpoints and new biomarkers, with minimal labeled data.

AI and Data Sciences Showcase:
sens8ai
sens8ai builds Darwin, the human layer of physical AI: a computing platform for continuous, sensor- and context-based health intelligence, so device makers, health systems and drug developers can build monitoring and trial endpoints for each individual, not the average patient.

Aaron Green

Biography
Aaron Green is President and Chief Executive Officer of OneMedNet, a healthcare technology company providing regulatory-grade, AI-ready real-world clinical data for research and drug development. He brings more than 20 years of leadership experience in healthcare technology, strategic planning, mergers and acquisitions, and commercial operations. Previously, he served as Vice President of Cloud Solutions at Optum and held senior leadership positions at Change Healthcare, overseeing cardiology, radiology, and medical imaging businesses. Earlier, he spent 15 years at McKesson, rising to Division Vice President of Sales. He holds a BS in Biochemistry from the University of Victoria, a Systems Analyst Diploma from Royal Roads University, and a management certificate from the Wharton School.

AI and Data Sciences Showcase:
OneMedNet

Kelly McVearry

Biography
Kelly M. McVearry, PhD, is Co-Founder and CEO of Bento Biology Platforms, a biotechnology company advancing decentralized clinical trials and inclusive precision medicine. A neuroscientist, technology executive, and patient advocate, she developed Bento's platform to expand participation in clinical research through at-home biosampling and digital patient engagement. Previously, she held leadership positions at Northrop Grumman Health Information Systems and Ekagra Software, where she helped advance clinical trial data technologies used in FDA regulatory review. She served as inaugural Chair of Lupus Therapeutics and on the NIH National Center for Advancing Translational Sciences Advisory Council. Dr. McVearry earned her PhD in Neuroscience from Georgetown University and a master's degree in Cognitive Psychology from Harvard University.

AI and Data Sciences Showcase:
Bento Biology

Elena Arzumanyan

Biography
Elena Arzumanyan, PhD, is Co-founder and CEO of Omabit, a biotechnology company developing AI-powered tools to make complex genomic and clinical data analysis accessible to life sciences researchers. She holds a PhD in Molecular Biology from Lomonosov Moscow State University and brings extensive experience in molecular diagnostics, assay development, and biotechnology entrepreneurship. Previously, she co-developed an early cancer detection assay covering nine cancers at Avida Biomed, which was acquired by Agilent Technologies, and led rare disease assay development at Natera. At Omabit, she focuses on applying artificial intelligence to integrate genomic and clinical evidence, accelerate biomarker discovery, and support more informed drug development decisions. Omabit is part of the StartX Summer 2026 founder community.

AI and Data Sciences Showcase:
Omabit

Esteban Toro

Biography
Esteban Toro, PhD, is Vice President of Research and Development at Twist Bioscience, where he leads technology and product development across genomics and synthetic biology. His expertise lies at the intersection of molecular biology, computational science, and artificial intelligence. He has led multidisciplinary teams developing technologies for DNA and RNA synthesis, protein engineering, next-generation sequencing, and antibody discovery. His work emphasizes integrating computational models with experimental biology to accelerate innovation and improve research efficiency. Dr. Toro earned his PhD from Stanford University and is affiliated with the Synthetic Biology Manufacturing of Advanced Materials Research Center at Washington University in St. Louis. He is also a co-founder and board member of Aterio, a data modeling company.

AI and Data Sciences Showcase:
Twist Biosciences